Phase I/II study of depatuxizumab mafodotin (ABT-414) monotherapy or combination with temozolomide in Japanese patients with/without EGFR -amplified recurrent glioblastoma
Narita, Yoshitaka, Muragaki, Yoshihiro, Maruyama, Takashi, Kagawa, Naoki, Asai, Katsunori, Kuroda, Junichiro, Kurozumi, Kazuhiko, Nagane, Motoo, Matsuda, Masahid, Ueki, Keisuke, Ocampo, Christopher Joseph, Matsumoto, Ikiru, Odagawa, Reiko, Nishimura, Yasuko, Mishima, Kazuhiko
Published in Journal of clinical oncology (20.05.2019)
Published in Journal of clinical oncology (20.05.2019)
Get full text
Journal Article
Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR
Calvo, Emiliano, Cleary, James M., Moreno, Victor, Gifford, Maryella, Roberts-Rapp, Lisa, Ansell, Peter J, Mittapalli, Rajendar K., Lee, Ho-Jin, Hu, Beibei, Barch, David, Ocampo, Christopher Joseph, Tolcher, Anthony W.
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Effect of therapeutic pressure on stability of EGFR amplification in glioblastoma
Ahluwalia, Manmeet Singh, Dimino, Cara R., Mansukhani, Mahesh M., Murty, Vundavalli V., Canoll, Peter, Narita, Yoshitaka, Muragaki, Yoshihiro, Gan, Hui Kong, Merrell, Ryan Thomas, Van Den Bent, Martin J., Zha, Zheng, Roberts-Rapp, Lisa, Jiang, Fang, Guseva, Maria, Bain, Earle E., Ocampo, Christopher Joseph, Ansell, Peter J, Lassman, Andrew B.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article